Navigation Links
Mapping the embryonic epigenome
Date:5/9/2013

7me3, involves the highly specific addition of three methyl groups to a type of histone named H3. "People have generally not thought of these two 'epigenetic' modifications as being very different in terms of their function," says Ren.

The current study puts an end to that notion. The researchers found in their analysis of those modifications across the genomereferred to, collectively, as the epigenomethat master genes that govern the regulation of early embryonic development tend largely to be switched off by H3K27me3 histone methylation. Meanwhile, those that orchestrate the later stages of cellular differentiation, when cells become increasingly committed to specific functions, are primarily silenced by DNA methylation.

"You can sort of glean the logic of animal development in this difference," says Ren. "Histone methylation is relatively easy to reverse. But reversing DNA methylation is a complex process, one that requires more resources and is much more likely to result in potentially deleterious mutations. So it makes sense that histone methylation is largely used to silence master genes that may be needed at multiple points during development, while DNA methylation is mostly used to switch off genes at later stages, when cells have already been tailored to specific functions, and those genes are less likely to be needed again."

The researchers also found that the human genome is peppered with more than 1,200 large regions that are consistently devoid of DNA methylation throughout development. It turns out that many of the genes considered master regulators of development are located in these regions, which the researchers call DNA methylation valleys (DMVs). Further, the team found that the DMVs are abnormally methylated in colon cancer cells. While it has long been known that aberrant DNA methylation plays an important role in various cancers, these results suggest that changes to the cell's DNA methylation machinery itself may b
'/>"/>

Contact: Rachel Steinhardt
Rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Mapping of cancer cell fuel pumps paves the way for new drugs
2. Brain Activity Mapping Project aims to understand the brain
3. Mapping effort charts restoration tack for Great Lakes
4. Carnegie debuts revolutionary biosphere mapping capability at AGU
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Influenza research: Can dynamic mapping reveal clues about seasonality?
7. Physics and math shed new light on biology by mapping the landscape of evolution
8. Geosphere: How geology, technology, modeling, and mapping see into Earths past and present
9. Road-mapping the Asian brain
10. Beyond base pairs: Mapping the functional genome
11. Speeding up drug discovery with rapid 3-D mapping of proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... survival and that of most other animals on earth. It ... discretely embedded into our everyday lives. Plants provide us with ... spite of their importance, very few of us could name ... us. True, most would have little difficulty in distinguishing between ...
... the Conservation Reserve Program (CRP) in the United States ... Questions abound regarding the fate of carbon sequestered in ... if the land is converted to grain crop production ... conserve the sequestered soil organic carbon (SOC). The effect ...
... 2009) - Researchers of the Michael G. DeGroote Institute ... that bacteria evolve into something that can make you ... issue of the Proceedings of the National Academy ... and assign risk to emerging diseases in the environment. ...
Cached Biology News:Will large amounts of soil carbon be released if grasslands are converted to energy crops? 2McMaster researchers discover new mode of how diseases evolve 2
(Date:4/20/2015)... April 20, 2015 Sinovac Biotech Ltd. (Nasdaq: ... today announced its unaudited financial results for the fourth ... Fourth Quarter 2014 Financial Highlights(Compared to the fourth ... million, a decrease of 11.4% from $22.9 million in ... stockpiling of H5N1 pandemic influenza vaccine of $0.1 million ...
(Date:4/17/2015)... , April 17, 2015  Centrillion Technologies, ... SBIR grant from the National Human Genome ... of Health (NIH). The grant will help ... the development of breakthrough genomic technologies, including ... fabricated substrates. Centrillion has been developing this ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery ... a Memorandum of Understanding with the Feinstein Institute ... New York to collaborate with the ... The collaboration brings together the drug ... clinical expertise of the Feinstein Institute in neurosciences ...
(Date:4/16/2015)... OSAKA, Japan , April 16, ... (CiRA) of Kyoto University and Takeda Pharmaceutical Company ... together to develop clinical applications of induced pluripotent ... diabetes mellitus, neurological disorders and cancer immunotherapy. The ... is designed to expedite multiple research projects for ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... Trial Data at the American Heart Association Late Breaker Session ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... , WEST LAFAYETTE, Ind. - Researchers have demonstrated ... called single-wall carbon nanotubes, possibly hastening their use ... electronics that are faster and consume less power ... used to revolutionize electronics by replacing conventional silicon ...
Cached Biology Technology:Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 2Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 3Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 4Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 5Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 6Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 7Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 8Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 9Imaging tool may aid nanoelectronics by screening tiny tubes 2Imaging tool may aid nanoelectronics by screening tiny tubes 3
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Biology Products: